Roche topped industry spending on R&D in 2013 as pharma's overall research investments rose by $723m, according to a new report.

The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).

GlobalData's PharmaLeaders: Global pharmaceutical benchmark report shows the world's leading 30 pharma companies spent $112bn on research and development in 2013, up $723m over the previous year.

Image: http://www.pmlive.com/